

Helena Earl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7922993/publications.pdf>

Version: 2024-02-01

16
papers

1,102
citations

949033

11
h-index

1051228

16
g-index

17
all docs

17
docs citations

17
times ranked

2094
citing authors

#	ARTICLE	IF	CITATIONS
1	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	5.1	148
2	Profiteering from vaccine inequity: nudge pharma towards "doing well by doing good". <i>BMJ</i> , The, 2021, 374, n2255.	3.0	0
3	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. <i>European Journal of Heart Failure</i> , 2020,	2.9	364
4	Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190.	1.3	11
5	Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz068.	1.4	6
6	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. <i>Lancet</i> , The, 2019, 393, 2599-2612.	6.3	225
7	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 108-120.	2.4	49
8	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 929-945.	5.1	58
9	Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. <i>Value in Health</i> , 2017, 20, 1311-1318.	0.1	31
10	Spotlight on landmark oncology trials: the latest evidence and novel trial designs. <i>BMC Medicine</i> , 2017, 15, 111.	2.3	3
11	New Model for Estimating Glomerular Filtration Rate in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2798-2805.	0.8	78
12	An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. <i>Ecanermedscience</i> , 2016, 10, 608.	0.6	5
13	Major milestones in translational oncology. <i>BMC Medicine</i> , 2016, 14, 110.	2.3	15
14	New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. <i>Journal of Medical Genetics</i> , 2016, 53, 655-661.	1.5	57
15	Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes " what does it all mean?. <i>BMC Medicine</i> , 2015, 13, 234.	2.3	39
16	Epirubicin as adjuvant therapy in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 189-195.	1.1	11